|
AU736282B2
(en)
|
1997-03-21 |
2001-07-26 |
Chugai Seiyaku Kabushiki Kaisha |
A preventive or therapeutic agent for sensitized T cell- mediated diseases comprising IL-6 antagonist as an active ingredient
|
|
US6787523B1
(en)
*
|
1997-12-02 |
2004-09-07 |
Neuralab Limited |
Prevention and treatment of amyloidogenic disease
|
|
US6761888B1
(en)
|
2000-05-26 |
2004-07-13 |
Neuralab Limited |
Passive immunization treatment of Alzheimer's disease
|
|
US7964192B1
(en)
|
1997-12-02 |
2011-06-21 |
Janssen Alzheimer Immunotherapy |
Prevention and treatment of amyloidgenic disease
|
|
US7790856B2
(en)
|
1998-04-07 |
2010-09-07 |
Janssen Alzheimer Immunotherapy |
Humanized antibodies that recognize beta amyloid peptide
|
|
TWI239847B
(en)
|
1997-12-02 |
2005-09-21 |
Elan Pharm Inc |
N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
|
|
US7588766B1
(en)
|
2000-05-26 |
2009-09-15 |
Elan Pharma International Limited |
Treatment of amyloidogenic disease
|
|
US20080050367A1
(en)
|
1998-04-07 |
2008-02-28 |
Guriq Basi |
Humanized antibodies that recognize beta amyloid peptide
|
|
US8703126B2
(en)
|
2000-10-12 |
2014-04-22 |
Genentech, Inc. |
Reduced-viscosity concentrated protein formulations
|
|
DE60139944D1
(de)
*
|
2000-10-12 |
2009-10-29 |
Genentech Inc |
Niederviskose konzentrierte proteinformulierungen
|
|
US7700751B2
(en)
|
2000-12-06 |
2010-04-20 |
Janssen Alzheimer Immunotherapy |
Humanized antibodies that recognize β-amyloid peptide
|
|
PE20020574A1
(es)
|
2000-12-06 |
2002-07-02 |
Wyeth Corp |
Anticuerpos humanizados que reconocen el peptido amiloideo beta
|
|
UA80091C2
(en)
|
2001-04-02 |
2007-08-27 |
Chugai Pharmaceutical Co Ltd |
Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
|
|
US20160279239A1
(en)
*
|
2011-05-02 |
2016-09-29 |
Immunomedics, Inc. |
Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
|
|
MY139983A
(en)
|
2002-03-12 |
2009-11-30 |
Janssen Alzheimer Immunotherap |
Humanized antibodies that recognize beta amyloid peptide
|
|
US20090010920A1
(en)
|
2003-03-03 |
2009-01-08 |
Xencor, Inc. |
Fc Variants Having Decreased Affinity for FcyRIIb
|
|
US20050158303A1
(en)
*
|
2003-04-04 |
2005-07-21 |
Genentech, Inc. |
Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
|
|
PT1610820E
(pt)
*
|
2003-04-04 |
2010-12-16 |
Novartis Ag |
Formulações de elevada concentração de anticorpos e proteínas
|
|
GB2401040A
(en)
|
2003-04-28 |
2004-11-03 |
Chugai Pharmaceutical Co Ltd |
Method for treating interleukin-6 related diseases
|
|
TWI306458B
(en)
|
2003-05-30 |
2009-02-21 |
Elan Pharma Int Ltd |
Humanized antibodies that recognize beta amyloid peptide
|
|
WO2005020923A2
(en)
*
|
2003-08-29 |
2005-03-10 |
Cedars-Sinai Medical Center |
Composition and method for the treatment of cancer and other physiologic conditions based on modulation of the ppar-gamma pathway and her-kinase axis
|
|
US9714282B2
(en)
|
2003-09-26 |
2017-07-25 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
|
DOP2005000002A
(es)
|
2004-01-09 |
2005-08-15 |
Pfizer |
"anticuerpos contra madcam"
|
|
WO2005072772A1
(en)
*
|
2004-01-30 |
2005-08-11 |
Suomen Punainen Risti Veripalvelu |
Pharmaceutical compositions
|
|
US7319032B2
(en)
|
2004-04-22 |
2008-01-15 |
Medtox |
Non-sugar sweeteners for use in test devices
|
|
US7884085B2
(en)
|
2004-05-12 |
2011-02-08 |
Baxter International Inc. |
Delivery of AS-oligonucleotide microspheres to induce dendritic cell tolerance for the treatment of autoimmune type 1 diabetes
|
|
US8728525B2
(en)
|
2004-05-12 |
2014-05-20 |
Baxter International Inc. |
Protein microspheres retaining pharmacokinetic and pharmacodynamic properties
|
|
EP1765294B1
(en)
|
2004-05-12 |
2008-09-24 |
Baxter International Inc. |
Nucleic acid microspheres, production and delivery thereof
|
|
CN103393601A
(zh)
*
|
2004-05-12 |
2013-11-20 |
巴克斯特国际公司 |
含有蛋白并在高浓度蛋白下显示可注射性的微球体
|
|
US7973134B2
(en)
|
2004-07-07 |
2011-07-05 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in anaplastic large cell lymphoma signaling pathways
|
|
EP3342782B1
(en)
|
2004-07-15 |
2022-08-17 |
Xencor, Inc. |
Optimized fc variants
|
|
CN101048427B
(zh)
|
2004-07-23 |
2015-01-14 |
健泰科生物技术公司 |
抗体或其片段的结晶
|
|
US20060051347A1
(en)
|
2004-09-09 |
2006-03-09 |
Winter Charles M |
Process for concentration of antibodies and therapeutic products thereof
|
|
US7935790B2
(en)
|
2004-10-04 |
2011-05-03 |
Cell Singaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in T-cell receptor signaling pathways
|
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
|
US8367805B2
(en)
|
2004-11-12 |
2013-02-05 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
|
US9200079B2
(en)
|
2004-11-12 |
2015-12-01 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
|
ES2396555T3
(es)
|
2004-12-15 |
2013-02-22 |
Janssen Alzheimer Immunotherapy |
Anticuerpos que reconocen péptido beta amiloide
|
|
EP1838348B1
(en)
|
2004-12-15 |
2013-06-26 |
Janssen Alzheimer Immunotherapy |
Humanized amyloid beta antibodies for use in improving cognition
|
|
US7807789B2
(en)
|
2004-12-21 |
2010-10-05 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in EGFR-signaling pathways
|
|
US20060142234A1
(en)
*
|
2004-12-23 |
2006-06-29 |
Guohua Chen |
Injectable non-aqueous suspension
|
|
PA8661401A1
(es)
*
|
2005-01-28 |
2006-09-08 |
Wyeth Corp |
Formulaciones del liquido polipeptido estabilizado
|
|
GT200600031A
(es)
*
|
2005-01-28 |
2006-08-29 |
|
Formulacion anticuerpo anti a beta
|
|
DE602006003108D1
(de)
*
|
2005-03-03 |
2008-11-27 |
Ajinomoto Kk |
Methode zur Verbesserung der Ausbeute bei der Proteinreinigung mittels Gelfiltrationschromatographie und Arginin
|
|
AU2014240252B2
(en)
*
|
2005-03-08 |
2016-10-06 |
Pfizer Products Inc |
Anti-CTLA-4 Antibody Compositions
|
|
AU2012200203B2
(en)
*
|
2005-03-08 |
2014-07-03 |
Pfizer Products Inc. |
Anti-CTLA-4 Antibody Compositions
|
|
EP1865986B1
(en)
*
|
2005-03-08 |
2016-02-17 |
Pfizer Products Inc. |
Anti-ctla-4 antibody compositions
|
|
CA3142945A1
(en)
|
2005-03-25 |
2006-10-05 |
Regeneron Pharmaceuticals, Inc. |
Histidine-buffered formulations of vegf antagonist
|
|
ES2407468T3
(es)
|
2005-04-18 |
2013-06-12 |
Yeda Research And Development Company Limited |
Formulaciones de anticuerpos anti-hepatitis B (HBV) estabilizadas
|
|
CA2606081C
(en)
|
2005-04-26 |
2013-09-17 |
Markus M. Heiss |
Combination of the application of antibodies for immunostimulation together with glucocorticoids
|
|
JP2008543839A
(ja)
|
2005-06-14 |
2008-12-04 |
アムジェン インコーポレーテッド |
自己緩衝タンパク質製剤
|
|
US20060286171A1
(en)
*
|
2005-06-17 |
2006-12-21 |
Tianhong Zhou |
Bone morphogenetic protein formulations
|
|
WO2007008943A2
(en)
|
2005-07-08 |
2007-01-18 |
Xencor, Inc. |
Optimized anti-ep-cam antibodies
|
|
WO2007027906A2
(en)
|
2005-08-31 |
2007-03-08 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in leukemia signaling pathways
|
|
KR101363777B1
(ko)
*
|
2005-09-30 |
2014-02-14 |
메디뮨 리미티드 |
인터루킨―１３ 항체 조성물
|
|
DK1931709T3
(en)
|
2005-10-03 |
2017-03-13 |
Xencor Inc |
FC VARIETIES WITH OPTIMIZED FC RECEPTOR BINDING PROPERTIES
|
|
US9309316B2
(en)
|
2005-12-20 |
2016-04-12 |
Bristol-Myers Squibb Company |
Stable subcutaneous protein formulations and uses thereof
|
|
AR058568A1
(es)
|
2005-12-20 |
2008-02-13 |
Bristol Myers Squibb Co |
Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
|
|
PT2253644E
(pt)
|
2005-12-20 |
2014-01-23 |
Bristol Myers Squibb Co |
Composições e métodos para a produção de uma composição
|
|
TW200738261A
(en)
|
2005-12-20 |
2007-10-16 |
Bristol Myers Squibb Co |
Stable protein formulations
|
|
JP5405122B2
(ja)
*
|
2005-12-21 |
2014-02-05 |
ワイス・エルエルシー |
低粘度のタンパク質製剤およびその用途
|
|
AR059066A1
(es)
|
2006-01-27 |
2008-03-12 |
Amgen Inc |
Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
|
|
HUE066795T2
(hu)
|
2006-03-15 |
2024-09-28 |
Alexion Pharma Inc |
Paroxysmalis nocturnalis haemoglobinuriában szenvedõ betegek kezelése egy komplement inhibitorral
|
|
CA2647111A1
(en)
*
|
2006-03-28 |
2007-10-04 |
F. Hoffmann-La Roche Ag |
Anti-igf-1r human monoclonal antibody formulation
|
|
US8784810B2
(en)
|
2006-04-18 |
2014-07-22 |
Janssen Alzheimer Immunotherapy |
Treatment of amyloidogenic diseases
|
|
SMP200800064B
(it)
*
|
2006-04-21 |
2009-11-06 |
Novartis Ag |
Composizioni farmaceutiche di anticorpi anti-cd40 antagonista
|
|
CA2654510C
(en)
|
2006-06-16 |
2015-03-17 |
Regeneron Pharmaceuticals, Inc. |
Vegf antagonist formulations suitable for intravitreal administration
|
|
AU2007281737B2
(en)
|
2006-08-04 |
2013-09-19 |
Baxter Healthcare S.A. |
Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes
|
|
US7939636B2
(en)
|
2006-08-11 |
2011-05-10 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in c-Src signaling pathways
|
|
RS53263B
(sr)
|
2006-08-14 |
2014-08-29 |
Xencor Inc. |
Optimizovana antitela usmerena na cd19
|
|
WO2008030505A2
(en)
|
2006-09-05 |
2008-03-13 |
Alexion Pharmaceuticals, Inc. |
Methods and compositions for the treatment of antibody mediated neuropathies
|
|
KR20090069330A
(ko)
*
|
2006-10-12 |
2009-06-30 |
와이어쓰 |
유백광/응집체를 감소시키기 위한 항체 용액 중의 이온 강도의 변화
|
|
CN101553504A
(zh)
*
|
2006-12-11 |
2009-10-07 |
豪夫迈·罗氏有限公司 |
Aβ抗体胃肠外制剂
|
|
AU2007234612B2
(en)
|
2006-12-14 |
2013-06-27 |
Johnson & Johnson Regenerative Therapeutics, Llc |
Protein stabilization formulations
|
|
US20090081659A1
(en)
|
2007-03-07 |
2009-03-26 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
|
|
EP1975184A3
(en)
|
2007-03-26 |
2008-11-26 |
Cell Signaling Technology, Inc. |
Serine or threonine phosphorylation sites
|
|
CA2681752A1
(en)
|
2007-03-29 |
2008-10-09 |
Abbott Laboratories |
Crystalline anti-human 1l-12 antibodies
|
|
KR101540823B1
(ko)
*
|
2007-03-30 |
2015-07-30 |
메디뮨 엘엘씨 |
항체 제제
|
|
CN101686939B
(zh)
*
|
2007-04-17 |
2013-03-27 |
巴克斯特国际公司 |
用于肺部投送的核酸微粒
|
|
US8003097B2
(en)
|
2007-04-18 |
2011-08-23 |
Janssen Alzheimer Immunotherapy |
Treatment of cerebral amyloid angiopathy
|
|
EP2145902A3
(en)
|
2007-04-19 |
2010-09-29 |
Peter Hornbeck |
Tyrosine phosphorylation sites and antibodies specific for them
|
|
EP1983003A3
(en)
|
2007-04-19 |
2009-03-11 |
Peter Hornbeck |
Tyrosine phosphorylation sites and antibodies specific for them
|
|
US7977462B2
(en)
|
2007-04-19 |
2011-07-12 |
Cell Signaling Technology, Inc. |
Tyrosine phosphorylation sites
|
|
US20090053831A1
(en)
|
2007-05-01 |
2009-02-26 |
Cell Signaling Technology, Inc. |
Tyrosine phosphorylation sites
|
|
EP2144624A1
(en)
*
|
2007-05-15 |
2010-01-20 |
Stryker Corporation |
Concentrated protein preparations of bone morphogenetic proteins and methods of use thereof
|
|
CA2693053C
(en)
|
2007-05-30 |
2021-01-05 |
Xencor, Inc. |
Methods and compositions for inhibiting cd32b expressing cells
|
|
EP2170283B1
(en)
|
2007-06-22 |
2019-01-09 |
Board of Regents, The University of Texas System |
Formation of stable submicron peptide or protein particles by thin film freezing
|
|
WO2009006301A2
(en)
*
|
2007-06-29 |
2009-01-08 |
Battelle Memorial Institute |
Protein stabilization
|
|
US7678764B2
(en)
|
2007-06-29 |
2010-03-16 |
Johnson & Johnson Regenerative Therapeutics, Llc |
Protein formulations for use at elevated temperatures
|
|
US20100189721A1
(en)
*
|
2007-07-06 |
2010-07-29 |
Smithkline Beecham Corporation |
Antibody formulations
|
|
JP2010531340A
(ja)
*
|
2007-07-10 |
2010-09-24 |
エフ．ホフマン−ラ ロシュ アーゲー |
新規処方物
|
|
ES2498040T3
(es)
|
2007-07-27 |
2014-09-24 |
Janssen Alzheimer Immunotherapy |
Tratamiento de enfermedades amiloidogénicas con anticuerpos anti-beta humanizados
|
|
CN101801405A
(zh)
|
2007-08-07 |
2010-08-11 |
先进科技及再生医学有限责任公司 |
包含于酸性水溶液中的gdf-5的蛋白质配方
|
|
WO2009037190A2
(en)
*
|
2007-09-21 |
2009-03-26 |
F. Hoffmann-La Roche Ag |
Pharmaceutical formulation for il-ir antibody
|
|
AU2008304111B2
(en)
*
|
2007-09-27 |
2014-04-24 |
Amgen Inc. |
Pharmaceutical formulations
|
|
JO3076B1
(ar)
|
2007-10-17 |
2017-03-15 |
Janssen Alzheimer Immunotherap |
نظم العلاج المناعي المعتمد على حالة apoe
|
|
US20090203043A1
(en)
|
2007-11-21 |
2009-08-13 |
Peter Hornbeck |
Protein phosphorylation by basophilic serine/threonine kinases in insulin signaling pathways
|
|
US20110177963A1
(en)
*
|
2007-11-28 |
2011-07-21 |
Yale Unversity |
Variation in the CHI3L1 Gene Influences Serum YKL-40 Levels, Asthma Risk and Lung Function
|
|
US8420081B2
(en)
*
|
2007-11-30 |
2013-04-16 |
Abbvie, Inc. |
Antibody formulations and methods of making same
|
|
US8883146B2
(en)
|
2007-11-30 |
2014-11-11 |
Abbvie Inc. |
Protein formulations and methods of making same
|
|
KR101616758B1
(ko)
|
2007-12-26 |
2016-04-29 |
젠코어 인코포레이티드 |
ＦｃＲｎ에 대한 변경된 결합성을 갖는 Ｆｃ 변이체
|
|
PE20091174A1
(es)
*
|
2007-12-27 |
2009-08-03 |
Chugai Pharmaceutical Co Ltd |
Formulacion liquida con contenido de alta concentracion de anticuerpo
|
|
US12492253B1
(en)
|
2008-02-25 |
2025-12-09 |
Xencor, Inc. |
Anti-human C5 antibodies
|
|
PT2993186T
(pt)
|
2008-03-14 |
2019-11-29 |
Biocon Ltd |
Anticorpo monoclonal e um método do mesmo
|
|
JP5599778B2
(ja)
*
|
2008-04-14 |
2014-10-01 |
デピュイ・シンセス・プロダクツ・エルエルシー |
液体緩衝ｇｄｆ−５製剤
|
|
WO2010042705A1
(en)
*
|
2008-10-09 |
2010-04-15 |
Medimmune, Llc |
Antibody formulation
|
|
RU2481824C2
(ru)
*
|
2008-10-29 |
2013-05-20 |
Аблинкс Н.В |
Препараты однодоменных антигенсвязывающих молекул
|
|
CN105646643A
(zh)
|
2008-10-29 |
2016-06-08 |
阿布林克斯公司 |
单域抗原结合性分子的纯化方法
|
|
US9067981B1
(en)
|
2008-10-30 |
2015-06-30 |
Janssen Sciences Ireland Uc |
Hybrid amyloid-beta antibodies
|
|
US8779094B2
(en)
*
|
2008-11-16 |
2014-07-15 |
Board Of Regents, The University Of Texas System |
Low viscosity highly concentrated suspensions
|
|
BRPI0916072A2
(pt)
*
|
2008-11-17 |
2015-11-10 |
Genentech Inc |
"uso de uma formulação, formulação farmacêutica, usos de um anticorpo 2h7 humanizado, método, método para aumentar a biodisponibilidade de um anticorpo e método de diálise in vitro"
|
|
MX2011005672A
(es)
*
|
2008-11-28 |
2011-06-20 |
Abbott Lab |
Composiciones de anticuerpo estables y metodos para estabilizar a las mismas.
|
|
EP2196476A1
(en)
*
|
2008-12-10 |
2010-06-16 |
Novartis Ag |
Antibody formulation
|
|
US20130064834A1
(en)
|
2008-12-15 |
2013-03-14 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating hypercholesterolemia using antibodies to pcsk9
|
|
JO3672B1
(ar)
|
2008-12-15 |
2020-08-27 |
Regeneron Pharma |
أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
|
|
CN102387814A
(zh)
*
|
2009-01-29 |
2012-03-21 |
米迪缪尼有限公司 |
延长体内半衰期的人抗il-6抗体及其在治疗肿瘤、自身免疫性疾病和炎症性疾病中的应用
|
|
EP2403873A1
(en)
|
2009-03-05 |
2012-01-11 |
Ablynx N.V. |
Novel antigen binding dimer-complexes, methods of making/avoiding and uses thereof
|
|
PE20120359A1
(es)
*
|
2009-03-06 |
2012-04-13 |
Genentech Inc |
Formulacion con anticuerpo
|
|
JP5755136B2
(ja)
|
2009-03-27 |
2015-07-29 |
旭化成メディカル株式会社 |
高濃度モノクローナル抗体溶液中のウイルス除去方法
|
|
US20100278822A1
(en)
*
|
2009-05-04 |
2010-11-04 |
Abbott Biotechnology, Ltd. |
Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
|
|
US8513259B2
(en)
|
2009-07-03 |
2013-08-20 |
Jdp Therapeutics, Inc. |
Non-sedating antihistamine injection formulations and methods of use thereof
|
|
US8263581B2
(en)
|
2009-07-03 |
2012-09-11 |
Jdp Therapeutics, Inc. |
Non-sedating antihistamine injection formulations and methods of use thereof
|
|
US9345661B2
(en)
|
2009-07-31 |
2016-05-24 |
Genentech, Inc. |
Subcutaneous anti-HER2 antibody formulations and uses thereof
|
|
US8454956B2
(en)
*
|
2009-08-31 |
2013-06-04 |
National Cheng Kung University |
Methods for treating rheumatoid arthritis and osteoporosis with anti-IL-20 antibodies
|
|
US9493578B2
(en)
|
2009-09-02 |
2016-11-15 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
|
EP2473528B1
(en)
|
2009-09-03 |
2014-12-03 |
Ablynx N.V. |
Stable formulations of polypeptides and uses thereof
|
|
AR078161A1
(es)
|
2009-09-11 |
2011-10-19 |
Hoffmann La Roche |
Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
|
|
JP2013507131A
(ja)
|
2009-10-09 |
2013-03-04 |
アーメイゲン・テクノロジーズ・インコーポレイテッド |
Ｃｎｓにおけるイズロン酸２−スルファターゼ活性を増加させるための方法および組成物
|
|
DK2494356T3
(en)
*
|
2009-10-26 |
2017-05-15 |
Genentech Inc |
ASSAYS FOR THE DETECTION OF ANTIBODIES SPECIFIC TO THERAPEUTIC ANTI-IGE ANTIBODIES AND THEIR USE OF ANAPHYLAXY
|
|
US20110117087A1
(en)
|
2009-10-26 |
2011-05-19 |
Reinhard Franze |
Method for the production of a glycosylated immunoglobulin
|
|
PL3721904T3
(pl)
*
|
2009-11-20 |
2022-01-31 |
Biocon Limited |
Formulacje przeciwciała t1h
|
|
JO3417B1
(ar)
*
|
2010-01-08 |
2019-10-20 |
Regeneron Pharma |
الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
|
|
AR080428A1
(es)
*
|
2010-01-20 |
2012-04-11 |
Chugai Pharmaceutical Co Ltd |
Formulaciones liquidas estabilizadas contentivas de anticuerpos
|
|
JP5859987B2
(ja)
*
|
2010-02-24 |
2016-02-16 |
アレコー リミテッド |
タンパク質製剤
|
|
SI3409289T1
(sl)
|
2010-02-26 |
2020-12-31 |
Novo Nordisk A/S |
Stabilni sestavki, ki vsebujejo protitelo
|
|
SG184355A1
(en)
|
2010-03-01 |
2012-11-29 |
Progenics Pharm Inc |
Concentrated protein formulations and uses thereof
|
|
PT2542257T
(pt)
|
2010-03-01 |
2017-10-09 |
Bayer Healthcare Llc |
Anticorpos monoclonais otimizados contra inibidor da via do fator tecidual (tfpi)
|
|
US20130171128A1
(en)
*
|
2010-03-02 |
2013-07-04 |
Amgen Inc. |
Reducing viscosity of pharmaceutical formulations
|
|
KR101878369B1
(ko)
|
2010-03-22 |
2018-07-16 |
제넨테크, 인크. |
단백질-함유 제제의 안정화에 유용한 조성물 및 방법
|
|
BR112012027828A2
(pt)
*
|
2010-05-03 |
2016-08-09 |
Genentech Inc |
composição de matéria, artigo de fabricação e método de redução da viscosidade de uma formulação contendo proteína e de preparação de uma formulação aquosa contendo proteína
|
|
RU2012153786A
(ru)
*
|
2010-05-28 |
2014-07-10 |
Ново Нордиск А/С |
Стабильные многодозовые композиции, содержащие антитело и консервант
|
|
JO3659B1
(ar)
*
|
2010-06-02 |
2020-08-27 |
Astellas Deutschland Gmbh |
أشكال جرعات بينداموستين عن طريق الفم وإستخداماته العلاجية
|
|
EP2399604A1
(en)
*
|
2010-06-25 |
2011-12-28 |
F. Hoffmann-La Roche AG |
Novel antibody formulation
|
|
PL2616090T3
(pl)
|
2010-09-17 |
2023-12-18 |
Takeda Pharmaceutical Company Limited |
Stabilizowanie immunoglobulin poprzez wodną formulację z histydyną o ph od słabo kwaśnego do obojętnego
|
|
MX366337B
(es)
*
|
2010-10-06 |
2019-07-05 |
Regeneron Pharma |
Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleucina-4 (il-4r).
|
|
KR101933197B1
(ko)
|
2010-11-08 |
2018-12-27 |
제넨테크, 인크. |
피하 투여용 항―ｉｌ―6 수용체 항체
|
|
TWI603739B
(zh)
|
2010-11-11 |
2017-11-01 |
艾伯維生物技術有限責任公司 |
具有增進高濃度之抗－ＴＮＦα抗體之液體調配物
|
|
KR20180023015A
(ko)
|
2011-01-13 |
2018-03-06 |
리제너론 파아마슈티컬스, 인크. |
혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도
|
|
CA2825778A1
(en)
|
2011-01-28 |
2012-08-02 |
Sanofi |
Pharmaceutical compositions comprising human antibodies to pcsk9
|
|
BR112013025866A2
(pt)
*
|
2011-04-07 |
2016-12-20 |
Glaxosmithkline Llc |
formulações com viscosidade reduzida
|
|
JO3283B1
(ar)
|
2011-04-26 |
2018-09-16 |
Sanofi Sa |
تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
|
|
UA116189C2
(uk)
|
2011-05-02 |
2018-02-26 |
Мілленніум Фармасьютікалз, Інк. |
КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
|
|
UY34054A
(es)
*
|
2011-05-02 |
2012-11-30 |
Millennium Pharm Inc |
FORMULACIÓN PARA ANTICUERPO ANTI-a(alfa)4B(Beta)7
|
|
AR087305A1
(es)
|
2011-07-28 |
2014-03-12 |
Regeneron Pharma |
Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
|
|
ES2773111T3
(es)
|
2011-09-16 |
2020-07-09 |
Regeneron Pharma |
Inhibidor de la proproteína convertasa subtilisina/kexina 9 (PCSK9) para su uso en la reducción de los niveles de lipoproteína (a)
|
|
SI2766397T1
(sl)
*
|
2011-10-11 |
2018-09-28 |
F. Hoffmann-La Roche Ag |
Izboljšano sestavljanje bispecifičnih protiteles
|
|
TWI589299B
(zh)
|
2011-10-11 |
2017-07-01 |
再生元醫藥公司 |
用於治療類風濕性關節炎之組成物及其使用方法
|
|
BR112014009866A2
(pt)
|
2011-10-25 |
2018-09-04 |
Onclave Therapeutics Limited |
formulações de anticorpos e métodos
|
|
EP2771031B1
(en)
|
2011-10-28 |
2018-04-18 |
Prothena Biosciences Limited |
Humanized antibodies that recognize alpha-synuclein
|
|
AU2012328524B2
(en)
*
|
2011-10-28 |
2017-05-18 |
Excelse Bio, Inc. |
Protein formulations containing amino acids
|
|
AU2012332767C1
(en)
|
2011-10-31 |
2017-02-02 |
Genentech, Inc. |
Antibody formulations
|
|
KR102063028B1
(ko)
|
2012-01-23 |
2020-01-07 |
리제너론 파아마슈티컬스, 인크. |
항-ａｎｇ2 항체를 함유하는 안정화된 제형
|
|
EP2807188B1
(en)
|
2012-01-27 |
2019-09-11 |
Prothena Biosciences Limited |
Humanized antibodies that recognize alpha-synuclein
|
|
EP3184542A1
(en)
|
2012-05-14 |
2017-06-28 |
Novo Nordisk A/S |
Stabilised protein solutions
|
|
SI2849723T1
(sl)
*
|
2012-05-18 |
2018-09-28 |
Genentech, Inc. |
Formulacije z visoko koncentracijo monoklonskih protiteles
|
|
AR092325A1
(es)
|
2012-05-31 |
2015-04-15 |
Regeneron Pharma |
Formulaciones estabilizadas que contienen anticuerpos anti-dll4 y kit
|
|
CN104520326A
(zh)
*
|
2012-06-21 |
2015-04-15 |
Ucb医药有限公司 |
药物制剂
|
|
US9221904B2
(en)
|
2012-07-19 |
2015-12-29 |
National Cheng Kung University |
Treatment of osteoarthritis using IL-20 antagonists
|
|
US8603470B1
(en)
|
2012-08-07 |
2013-12-10 |
National Cheng Kung University |
Use of IL-20 antagonists for treating liver diseases
|
|
US8852588B2
(en)
|
2012-08-07 |
2014-10-07 |
National Cheng Kung University |
Treating allergic airway disorders using anti-IL-20 receptor antibodies
|
|
FR2994390B1
(fr)
|
2012-08-10 |
2014-08-15 |
Adocia |
Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee
|
|
US8613919B1
(en)
|
2012-08-31 |
2013-12-24 |
Bayer Healthcare, Llc |
High concentration antibody and protein formulations
|
|
US9592297B2
(en)
|
2012-08-31 |
2017-03-14 |
Bayer Healthcare Llc |
Antibody and protein formulations
|
|
FR2995213A1
(fr)
*
|
2012-09-12 |
2014-03-14 |
Lfb Biotechnologies |
Seringue contenant une composition, notamment pharmaceutique, comprenant des immunoglobulines, son procede de fabrication et son utilisation
|
|
UA118441C2
(uk)
|
2012-10-08 |
2019-01-25 |
Протена Біосаєнсиз Лімітед |
Антитіло, що розпізнає альфа-синуклеїн
|
|
US20150239970A1
(en)
*
|
2012-10-25 |
2015-08-27 |
Medimmune, Llc |
Stable, Low Viscosity Antibody Formulation
|
|
EP2727602A1
(en)
|
2012-10-31 |
2014-05-07 |
Takeda GmbH |
Method for preparation of a high concentration liquid formulation of an antibody
|
|
UA117466C2
(uk)
|
2012-12-13 |
2018-08-10 |
Мерк Шарп Енд Доме Корп. |
СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
|
|
US10111953B2
(en)
|
2013-05-30 |
2018-10-30 |
Regeneron Pharmaceuticals, Inc. |
Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
|
|
JP6563910B2
(ja)
|
2013-07-04 |
2019-08-21 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
血清サンプル中の抗薬物抗体を検出するための干渉抑制イムノアッセイ
|
|
US10513555B2
(en)
*
|
2013-07-04 |
2019-12-24 |
Prothena Biosciences Limited |
Antibody formulations and methods
|
|
US10189899B2
(en)
|
2013-07-23 |
2019-01-29 |
Biocon Limited |
Use of a CD6 binding partner and method based thereon
|
|
IL312865B2
(en)
*
|
2013-09-11 |
2025-06-01 |
Eagle Biologics Inc |
Liquid protein formulations containing viscosity-lowering agents
|
|
EP3062814A1
(en)
*
|
2013-10-29 |
2016-09-07 |
Albumedix A/S |
Antibody composition
|
|
US10428157B2
(en)
|
2013-11-12 |
2019-10-01 |
Sanofi Biotechnology |
Dosing regimens for use with PCSK9 inhibitors
|
|
EP2946767B1
(en)
|
2014-05-23 |
2016-10-05 |
Ares Trading S.A. |
Liquid pharmaceutical composition
|
|
PL2946765T3
(pl)
|
2014-05-23 |
2017-08-31 |
Ares Trading S.A. |
Ciekła kompozycja farmaceutyczna
|
|
EP2946766B1
(en)
|
2014-05-23 |
2016-03-02 |
Ares Trading S.A. |
Liquid pharmaceutical composition
|
|
US11357857B2
(en)
|
2014-06-20 |
2022-06-14 |
Comera Life Sciences, Inc. |
Excipient compounds for protein processing
|
|
US10478498B2
(en)
|
2014-06-20 |
2019-11-19 |
Reform Biologics, Llc |
Excipient compounds for biopolymer formulations
|
|
WO2015196091A1
(en)
|
2014-06-20 |
2015-12-23 |
Reform Biologics, Llc |
Viscosity-reducing excipient compounds for protein formulations
|
|
KR20230074283A
(ko)
|
2014-07-16 |
2023-05-26 |
사노피 바이오테크놀로지 |
이형접합성 가족성 고콜레스테롤혈증(heFH) 환자의 치료방법
|
|
RS58957B1
(sr)
|
2014-07-18 |
2019-08-30 |
Sanofi Sa |
Postupak za predviđanje ishoda tretmana sa afliberceptom kod pacijenta za kog se sumnja da boluje od raka
|
|
WO2016019969A1
(en)
|
2014-08-08 |
2016-02-11 |
Ludwig-Maximilians-Universität München |
Subcutaneously administered bispecific antibodies for use in the treatment of cancer
|
|
SG11201702614SA
(en)
|
2014-10-01 |
2017-04-27 |
Eagle Biolog Inc |
Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
|
|
US20170247460A1
(en)
*
|
2014-10-18 |
2017-08-31 |
Pfizer Inc. |
Anti-il-7r antibody compositions
|
|
ES2964713T3
(es)
*
|
2014-10-23 |
2024-04-09 |
Amgen Inc |
Reducción de la viscosidad de formulaciones farmacéuticas
|
|
MA41115A
(fr)
|
2014-12-02 |
2017-10-10 |
Biogen Int Neuroscience Gmbh |
Procédé de traitement de la maladie d'alzheimer
|
|
WO2016115475A1
(en)
*
|
2015-01-18 |
2016-07-21 |
Biogen Ma Inc. |
Anti-cd40 antibody formulations
|
|
US10550173B2
(en)
|
2015-02-19 |
2020-02-04 |
Compugen, Ltd. |
PVRIG polypeptides and methods of treatment
|
|
IL254039B2
(en)
|
2015-02-19 |
2023-12-01 |
Compugen Ltd |
Anti-pvrig antibodies and methods of use
|
|
AR103726A1
(es)
|
2015-02-27 |
2017-05-31 |
Merck Sharp & Dohme |
Cristales de anticuerpos monoclonales anti-pd-1 humanos
|
|
AU2016282334B2
(en)
|
2015-06-24 |
2022-07-21 |
F. Hoffmann-La Roche Ag |
Anti-transferrin receptor antibodies with tailored affinity
|
|
EP3971211A1
(en)
|
2015-07-13 |
2022-03-23 |
Compugen Ltd. |
Hide1 compositions and methods
|
|
ES2964640T3
(es)
|
2015-08-13 |
2024-04-08 |
Amgen Inc |
Filtración en profundidad cargada de proteínas de unión al antígeno
|
|
EA201890519A1
(ru)
|
2015-08-18 |
2018-07-31 |
Ридженерон Фармасьютикалз, Инк. |
Ингибирующие антитела против pcsk9 для лечения пациентов с гиперлипидемией, подвергающихся аферезу липопротеинов
|
|
AR106189A1
(es)
|
2015-10-02 |
2017-12-20 |
Hoffmann La Roche |
ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
|
|
MX2018003822A
(es)
|
2015-10-02 |
2018-06-22 |
Hoffmann La Roche |
Anticuerpos biespecificos contra el cd20 humano y el receptor de transferrina humano y metodos de uso.
|
|
WO2017066714A1
(en)
|
2015-10-16 |
2017-04-20 |
Compugen Ltd. |
Anti-vsig1 antibodies and drug conjugates
|
|
KR20210157427A
(ko)
|
2015-12-03 |
2021-12-28 |
리제너론 파마슈티칼스 인코포레이티드 |
항-vegf로 치료된 연령-관련 황반 변성을 앓고 있는 환자에서의 임상 결과와 유전적 변이체를 연관시키는 방법
|
|
US10994011B2
(en)
|
2015-12-18 |
2021-05-04 |
Astellas Pharma Inc. |
Pharmaceutical composition comprising anti-human TSLP receptor antibody
|
|
US10525137B2
(en)
|
2015-12-30 |
2020-01-07 |
Genentech, Inc. |
Formulations with reduced degradation of polysorbate
|
|
EP3448425A1
(en)
*
|
2016-04-28 |
2019-03-06 |
Biogen MA Inc. |
Pharmaceutical compositions and dosage regimens for clinical use of anti-blood dendritic cell antigen 2 antibodies
|
|
CA3024618A1
(en)
|
2016-05-27 |
2017-11-30 |
Alexion Pharmaceuticals, Inc. |
Methods for treatment of refractory generalized myasthenia gravis
|
|
WO2017214452A1
(en)
|
2016-06-08 |
2017-12-14 |
Xencor, Inc. |
Treatment of igg4-related diseases with anti-cd19 antibodies crossbinding to cd32b
|
|
EP3254671B1
(en)
*
|
2016-06-10 |
2019-11-13 |
Octapharma AG |
High concentration immunoglobulin composition for pharmaceutical application
|
|
KR102585976B1
(ko)
|
2016-08-17 |
2023-10-05 |
컴퓨젠 엘티디. |
항-tigit 항체, 항-pvrig 항체 및 이들의 조합
|
|
US20190216925A1
(en)
|
2016-09-16 |
2019-07-18 |
Leukocare Ag |
A Novel Method for Stabilization of a Biopharmaceutical Drug Product During Processing
|
|
EP3512939B1
(en)
|
2016-09-16 |
2026-06-17 |
Leukocare AG |
A novel method for obtaining efficient viral vector-based compositions for vaccination or gene therapy
|
|
JP7275027B2
(ja)
|
2016-10-06 |
2023-05-17 |
アムジェン インコーポレイテッド |
粘度低下タンパク質医薬製剤
|
|
DK3529269T3
(da)
|
2016-10-19 |
2026-02-23 |
Invenra Inc |
Antistof-konstruktioner
|
|
KR102514528B1
(ko)
|
2016-10-21 |
2023-03-27 |
바이오콘 리미티드 |
루푸스 치료를 위한 단일클론항체 및 이의 치료방법
|
|
ES3064802T3
(en)
|
2016-10-21 |
2026-04-29 |
Amgen Inc |
Pharmaceutical formulations and methods of making the same
|
|
WO2018115485A1
(en)
|
2016-12-22 |
2018-06-28 |
Pierfrancesco Tassone |
A monoclonal antibody targeting a unique sialoglycosilated cancer-associated epitope of cd43
|
|
JP7630906B2
(ja)
|
2017-02-01 |
2025-02-18 |
イェール・ユニヴァーシティー |
利尿薬耐性の治療
|
|
JP7377596B2
(ja)
|
2017-02-22 |
2023-11-10 |
アムジエン・インコーポレーテツド |
低粘度、高濃度エボロクマブ製剤及びそれらの製造方法
|
|
TWI911431B
(zh)
|
2017-03-01 |
2026-01-11 |
英商梅迪繆思有限公司 |
抗rsv單株抗體配製物
|
|
WO2018181876A1
(ja)
|
2017-03-31 |
2018-10-04 |
Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 |
水性製剤及び注射器入り水性製剤、並びに、抗体タンパク脱凝集剤及び抗体タンパク脱凝集方法
|
|
CA3044082A1
(en)
|
2017-04-03 |
2018-10-11 |
Immunomedics, Inc. |
Subcutaneous administration of antibody-drug conjugates for cancer therapy
|
|
CN110913906A
(zh)
|
2017-05-02 |
2020-03-24 |
默沙东公司 |
抗lag3抗体的制剂和抗lag3抗体与抗pd-1抗体的共制剂
|
|
JOP20190260A1
(ar)
|
2017-05-02 |
2019-10-31 |
Merck Sharp & Dohme |
صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
|
|
JP7348072B2
(ja)
|
2017-06-01 |
2023-09-20 |
コンピュジェン リミテッド |
三重併用抗体療法
|
|
KR102787394B1
(ko)
|
2017-07-14 |
2025-03-26 |
화이자 인크. |
MAdCAM에 대한 항체
|
|
ES2965486T3
(es)
|
2017-07-27 |
2024-04-15 |
Alexion Pharma Inc |
Formulaciones de anticuerpos anti-C5 de alta concentración
|
|
US20210363259A1
(en)
*
|
2017-08-22 |
2021-11-25 |
Biogen Ma Inc. |
Pharmaceutical compositions and dosage regimens containing anti-alpha(v)beta(6) antibodies
|
|
MD3672631T3
(ro)
*
|
2017-08-22 |
2023-09-30 |
Biogen Ma Inc |
Compoziții farmaceutice conținând anticorpi anti-beta amiloidici
|
|
EP3678700B1
(en)
|
2017-09-05 |
2024-06-19 |
Merck Sharp & Dohme LLC |
Compounds for reducing the viscosity of biological formulations
|
|
JP7518764B2
(ja)
|
2017-10-26 |
2024-07-18 |
アレクシオン ファーマシューティカルズ， インコーポレイテッド |
発作性夜間ヘモグロビン尿症（ＰＮＨ）および非典型溶血性尿毒症症候群（ａＨＵＳ）の処置のための抗Ｃ５抗体の投薬量および投与
|
|
WO2019099921A2
(en)
|
2017-11-17 |
2019-05-23 |
Amgen Inc. |
Vegfr-fc fusion protein formulations
|
|
MX2020005630A
(es)
*
|
2017-11-30 |
2020-08-20 |
Bio Thera Solutions Ltd |
Formulacion liquida de anticuerpos humanizados para el tratamiento de enfermedades relacionadas con il-6.
|
|
KR20200093621A
(ko)
|
2017-11-30 |
2020-08-05 |
리제너론 파아마슈티컬스, 인크. |
혈관형성 눈 장애를 치료하기 위한 vegf 길항제의 용도
|
|
SG11202006157VA
(en)
|
2018-01-05 |
2020-07-29 |
Corvidia Therapeutics Inc |
Methods for treating il-6 mediated inflammation without immunosuppression
|
|
WO2019153200A1
(zh)
|
2018-02-08 |
2019-08-15 |
北京韩美药品有限公司 |
抗pd-1/抗her2天然抗体结构样异源二聚体形式双特异抗体及其制备
|
|
KR20220098056A
(ko)
|
2018-02-09 |
2022-07-08 |
제넨테크, 인크. |
비만 세포 매개 염증성 질환에 대한 치료 및 진단 방법
|
|
AU2019236105B2
(en)
|
2018-03-14 |
2025-07-31 |
Boehringer Ingelheim International Gmbh |
Use of anti-IL-36R antibodies for treatment of generalized pustular psoriasis
|
|
CA3094749A1
(en)
*
|
2018-03-26 |
2019-10-03 |
Novartis Ag |
Methods of treating chronic spontaneous urticaria using ligelizumab
|
|
RS67656B1
(sr)
|
2018-05-10 |
2026-02-27 |
Regeneron Pharma |
Formulacije koje sadrže visoke koncentracije fuzionog proteina vegf receptora
|
|
US11519020B2
(en)
|
2018-05-25 |
2022-12-06 |
Regeneron Pharmaceuticals, Inc. |
Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
|
|
CN113227127A
(zh)
|
2018-06-05 |
2021-08-06 |
伦敦大学国王学院 |
向胃肠系统递送酬载的btnl3/8导引构建体
|
|
JP7538723B2
(ja)
|
2018-06-28 |
2024-08-22 |
アレクシオン ファーマシューティカルズ， インコーポレイテッド |
抗ｃ５抗体の産生方法
|
|
TW202011995A
(zh)
*
|
2018-07-03 |
2020-04-01 |
比利時商葛萊伯格有限公司 |
高濃度液體抗體配製物
|
|
ES3014697T3
(en)
|
2018-07-19 |
2025-04-24 |
Ichnos Sciences S A |
Liquid antibody formulation
|
|
BR112021004126A2
(pt)
*
|
2018-09-05 |
2021-05-25 |
Ventria Bioscience Inc. |
formulação profilática e/ou terapêutica estabilizada e método profilático ou terapêutico
|
|
SG11202101980VA
(en)
|
2018-09-12 |
2021-03-30 |
Silverback Therapeutics Inc |
Methods and composition for the treatment of disease with immune stimulatory conjugates
|
|
MX2021004356A
(es)
|
2018-10-18 |
2021-05-31 |
Merck Sharp & Dohme Llc |
Formulaciones de anticuerpos anti-rsv y metodos de uso de las mismas.
|
|
US20210353713A1
(en)
*
|
2018-10-26 |
2021-11-18 |
Amgen Inc. |
Formulations comprising a tris buffer and a protein
|
|
MA54089A
(fr)
|
2018-10-31 |
2022-02-09 |
Merck Sharp & Dohme |
Anticorps anti-pd-1 humain et procédés d'utilisation associés
|
|
JP7503056B6
(ja)
|
2018-11-07 |
2024-07-16 |
メルク・シャープ・アンド・ドーム・エルエルシー |
抗ｌａｇ３抗体および抗ｐｄ－１抗体の共－製剤
|
|
CA3126499A1
(en)
|
2019-01-17 |
2020-07-23 |
LETI Pharma S.L. |
Methods of purifying an allergen extract
|
|
JP7542543B2
(ja)
|
2019-01-31 |
2024-08-30 |
サノフィ・バイオテクノロジー |
若年性特発性関節炎を治療するための抗ｉｌ－６受容体抗体
|
|
US12643950B1
(en)
|
2019-02-07 |
2026-06-02 |
Takeda Pharmaceutical Company Limited |
Autoinjector comprising high concentration formulation of vedolizumab
|
|
PE20212185A1
(es)
|
2019-02-18 |
2021-11-11 |
Lilly Co Eli |
Formulacion de anticuerpos terapeuticos
|
|
JP2022521624A
(ja)
*
|
2019-02-26 |
2022-04-11 |
イノベント バイオロジックス （スウツォウ） カンパニー，リミテッド |
抗ｃｄ４７抗体を含む製剤、その調製方法および使用
|
|
US11730812B2
(en)
*
|
2019-03-08 |
2023-08-22 |
Boehringer Ingelheim International Gmbh |
Anti-IL-36R antibody formulations
|
|
JP2022545312A
(ja)
|
2019-04-24 |
2022-10-27 |
サノフィ・バイオテクノロジー |
関節リウマチの診断及び処置の方法
|
|
CA3142710A1
(en)
|
2019-06-04 |
2020-12-10 |
Sanofi Biotechnology |
Compositions and methods for treating pain in subjects with rheumatoid arthritis
|
|
MX2021015533A
(es)
|
2019-06-19 |
2022-02-10 |
Silverback Therapeutics Inc |
Anticuerpos anti-mesotelina e inmunoconjugados de los mismos.
|
|
US20220280643A1
(en)
*
|
2019-07-29 |
2022-09-08 |
Mark White |
Anti-pvrig antibodies formulations and uses thereof
|
|
WO2021023267A1
(zh)
|
2019-08-07 |
2021-02-11 |
信达生物制药(苏州)有限公司 |
包含抗pd-1/her2双特异性抗体的制剂及其制备方法和用途
|
|
JP7792137B2
(ja)
*
|
2019-08-30 |
2025-12-25 |
カシーヴ バイオサイエンシズ，リミテッド・ライアビリティ・カンパニー |
高濃度の薬理学的に活性な抗体の新規製剤
|
|
CN112516090B
(zh)
*
|
2019-09-18 |
2023-06-20 |
上海复旦张江生物医药股份有限公司 |
抗体偶联药物的药物组合、冷冻干燥剂及制备方法、用途
|
|
EP3808777A1
(en)
|
2019-10-16 |
2021-04-21 |
Glenmark Specialty S.A. |
Stable liquid antibody formulations
|
|
WO2021091605A1
(en)
*
|
2019-11-04 |
2021-05-14 |
Compugen Ltd. |
Combination therapy with anti-pvrig antibodies formulations and anti-pd-1 antibodies
|
|
US11179473B2
(en)
|
2020-02-21 |
2021-11-23 |
Silverback Therapeutics, Inc. |
Nectin-4 antibody conjugates and uses thereof
|
|
CN115297838A
(zh)
*
|
2020-02-24 |
2022-11-04 |
麦迪穆医学免疫有限责任公司 |
抗内皮脂肪酶抗体的制剂
|
|
AU2021262609A1
(en)
|
2020-05-01 |
2022-12-22 |
Kashiv Biosciences, Llc |
An improved process of purification of protein
|
|
CA3182314A1
(en)
*
|
2020-05-01 |
2021-11-04 |
Kashiv Biosciences, Llc |
An improved process of purification of protein
|
|
AU2021279035A1
(en)
*
|
2020-05-29 |
2023-02-02 |
Aduro Biotech Holding, Europe B.V. |
Methods of treating IgA nephropathy with an APRIL binding antibody
|
|
US12558423B2
(en)
|
2020-05-29 |
2026-02-24 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody-containing formulation
|
|
CN116194478A
(zh)
|
2020-06-24 |
2023-05-30 |
阿雷克森制药公司 |
皮下（sc）施用抗c5抗体治疗补体相关病症
|
|
KR20230047361A
(ko)
|
2020-07-01 |
2023-04-07 |
아르스 파마슈티컬스 인크. |
항-asgr1 항체 접합체 및 이의 용도
|
|
MX2023000763A
(es)
|
2020-07-17 |
2023-02-13 |
Boehringer Ingelheim Int |
Anticuerpos anti-il-36r para el tratamiento de dermatosis neutrofilas.
|
|
CA3217391A1
(en)
*
|
2020-07-27 |
2022-02-03 |
Youwei ZHU |
Formulation of novel bispecific anti-cd3/cd20 polypeptide complex
|
|
KR20220028972A
(ko)
*
|
2020-08-31 |
2022-03-08 |
(주)셀트리온 |
안정한 약제학적 제제
|
|
WO2022092183A1
(ja)
*
|
2020-10-30 |
2022-05-05 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
医薬組成物
|
|
CN117582496A
(zh)
*
|
2020-12-18 |
2024-02-23 |
美勒斯公司 |
抗体组合物
|
|
CN114762727A
(zh)
*
|
2021-01-15 |
2022-07-19 |
海正生物制药有限公司 |
一种稳定的帕妥珠单抗的药物组合物
|
|
EP4305207A2
(en)
|
2021-03-12 |
2024-01-17 |
Boehringer Ingelheim International GmbH |
Biomarkers associated with anti-il-36r antibody treatment in generalized pustular psoriasis
|
|
AU2022236913A1
(en)
*
|
2021-03-16 |
2023-10-26 |
Kashiv Biosciences, Llc |
Novel formulation of fusion protein
|
|
WO2022245877A1
(en)
|
2021-05-17 |
2022-11-24 |
Curia Ip Holdings, Llc |
Sars-cov-2 spike protein antibodies
|
|
US20220372114A1
(en)
|
2021-05-17 |
2022-11-24 |
Curia Ip Holdings, Llc |
Sars-cov-2 spike protein antibodies
|
|
US20240269279A1
(en)
*
|
2021-06-14 |
2024-08-15 |
Novartis Ag |
PHARMACEUTICAL FORMULATION CONTAINING AN ANTI-IgE ANTIBODY
|
|
CA3224052A1
(en)
*
|
2021-06-18 |
2022-12-22 |
Techmix, Llc |
Bovine supplement for neonatal calves
|
|
KR20240046243A
(ko)
*
|
2021-08-16 |
2024-04-08 |
메디뮨 엘엘씨 |
항-il-13 항체 제제
|
|
CN114159555A
(zh)
*
|
2021-12-08 |
2022-03-11 |
江西赛基生物技术有限公司 |
抗原蛋白冻干小球及其制备方法
|
|
KR102839225B1
(ko)
*
|
2022-03-02 |
2025-07-29 |
노보 노르디스크 헬스 케어 악티엔게젤샤프트 |
Fviii 모방 이중특이적 항체의 주 1회 투여 방법
|
|
KR102839278B1
(ko)
*
|
2022-03-02 |
2025-07-30 |
노보 노르디스크 헬스 케어 악티엔게젤샤프트 |
Fviii 모방 이중특이적 항체의 월 1회 투여 방법
|
|
KR102868672B1
(ko)
*
|
2022-03-02 |
2025-10-14 |
노보 노르디스크 헬스 케어 악티엔게젤샤프트 |
Fviii 모방 이중특이적 항체를 2주마다 1회 투여하는 방법
|
|
EP4615502A1
(en)
|
2022-11-07 |
2025-09-17 |
Upstream Bio, Inc. |
Pharmaceutical compositions comprising anti-human tslp receptor antibodies and methods of using the same
|
|
CN121399161A
(zh)
*
|
2023-06-23 |
2026-01-23 |
诺和诺德医疗保健公司 |
每两个月一次施用fviii模拟双特异性抗体的方法
|
|
WO2025010086A1
(en)
*
|
2023-07-05 |
2025-01-09 |
Genentech, Inc. |
Anti-ige antibody therapy for multiple food allergies
|
|
CA3237624A1
(en)
*
|
2023-07-28 |
2025-04-24 |
Genentech, Inc. |
NEW USES FOR OMALIZUMAB
|